Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients.

Walker IF, Shi O, Hicks JP, Elsey H, Wei X, Menzies D, Lan Z, Falzon D, Migliori GB, Pérez-Guzmán C, Vargas MH, García-García L, Sifuentes Osornio J, Ponce-De-León A, van der Walt M, Newell JN.

Eur Respir J. 2019 Jul 11;54(1). pii: 1800353. doi: 10.1183/13993003.00353-2018. Print 2019 Jul.

PMID:
31073080
2.

Tuberculosis research questions identified through the WHO policy guideline development process.

Gebreselassie N, Falzon D, Zignol M, Kasaeva T.

Eur Respir J. 2019 Mar 18;53(3). pii: 1802407. doi: 10.1183/13993003.02407-2018. Print 2019 Mar. No abstract available.

PMID:
30886024
3.

The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.

Falzon D, Jaramillo E, Gilpin C, Weyer K.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S365-S367. doi: 10.1093/cid/ciy710. No abstract available.

4.

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.

Weyer K, Falzon D, Jaramillo E.

Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230. No abstract available.

5.

Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.

Nsengiyumva NP, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman A, Falzon D, Schwartzman K.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801363. doi: 10.1183/13993003.01363-2018. Print 2018 Nov.

6.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

7.

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.

Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P.

PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.

8.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
9.

The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.

Halleux CM, Falzon D, Merle C, Jaramillo E, Mirzayev F, Olliaro P, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1701643. doi: 10.1183/13993003.01643-2017. Print 2018 Mar. No abstract available.

PMID:
29567719
10.

The impact of digital health technologies on tuberculosis treatment: a systematic review.

Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, Falzon D, Schwartzman K; Collaborative group on the impact of digital technologies on TB.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701596. doi: 10.1183/13993003.01596-2017. Print 2018 Jan.

11.

Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey.

Tagliani E, Hassan MO, Waberi Y, De Filippo MR, Falzon D, Dean A, Zignol M, Supply P, Abdoulkader MA, Hassangue H, Cirillo DM.

Sci Rep. 2017 Dec 15;7(1):17672. doi: 10.1038/s41598-017-17705-3.

12.

Determinants of site of tuberculosis disease: An analysis of European surveillance data from 2003 to 2014.

Sotgiu G, Falzon D, Hollo V, Ködmön C, Lefebvre N, Dadu A, van der Werf M.

PLoS One. 2017 Nov 20;12(11):e0186499. doi: 10.1371/journal.pone.0186499. eCollection 2017.

13.

The Evidence is Out There; Let's Keep on Looking For It Re: The Evidence-Base Surrounding Lung Isolation is Often Wider Than Described.

Falzon D, Alston PR, Coley E, Montgomery K.

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):e15-e16. doi: 10.1053/j.jvca.2017.08.003. Epub 2017 Aug 3. No abstract available.

PMID:
29146171
14.

Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.

Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M; Global Task Force on digital health for TB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701632. doi: 10.1183/13993003.01632-2017. Print 2017 Nov. No abstract available.

15.

Awake fibreoptic intubation for caesarean section in a patient with spondyloepiphyseal dysplasia congenita.

Falzon D, Burns R, Theodosiou CA, Cooper ES.

Int J Obstet Anesth. 2018 Feb;33:96-97. doi: 10.1016/j.ijoa.2017.09.004. Epub 2017 Sep 28. No abstract available.

PMID:
29103886
16.

Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.

Ahmad Khan F, Salim MAH, du Cros P, Casas EC, Khamraev A, Sikhondze W, Benedetti A, Bastos M, Lan Z, Jaramillo E, Falzon D, Menzies D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700061. doi: 10.1183/13993003.00061-2017. Print 2017 Jul.

17.

Tuberculosis control, and the where and why of artificial intelligence.

Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M.

ERJ Open Res. 2017 Jun 21;3(2). pii: 00056-2017. doi: 10.1183/23120541.00056-2017. eCollection 2017 Apr. Review.

18.

The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership.

Wang L, Li R, Xu C, Zhang H, Ruan Y, Chen M, Wang D, Dirlikov E, Du X, Zhao J, Zhao Y, Wang S, Liu Y, Li L, Falzon D, Sun Y, Wang Y, Schwartländer B, Scano F.

PLoS One. 2017 Jun 19;12(6):e0177536. doi: 10.1371/journal.pone.0177536. eCollection 2017.

19.

The Internet of Things to come: digital technologies and the End TB Strategy.

Falzon D, Raviglione M.

BMJ Glob Health. 2016 Aug 12;1(2):e000038. doi: 10.1136/bmjgh-2016-000038. eCollection 2016. No abstract available.

20.

Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.

Falzon D, Jaramillo E, Gilpin C, Weyer K.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700317. doi: 10.1183/13993003.00317-2017. Print 2017 Apr. No abstract available.

21.

Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.

Yassin MA, Jaramillo E, Wandwalo E, Falzon D, Scardigli A, Kunii O, Weyer K.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700081. doi: 10.1183/13993003.00081-2017. Print 2017 Mar. No abstract available.

22.

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.

Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602308. doi: 10.1183/13993003.02308-2016. Print 2017 Mar.

23.

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.

Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, de Colombani P, Dadu A, Dara M, Story A, Skrahina A.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602049. doi: 10.1183/13993003.02049-2016. Print 2017 Mar. No abstract available.

24.

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience.

Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S62-S63. doi: 10.1016/j.ijmyco.2016.11.014. Epub 2016 Nov 23.

25.

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.

Trauer JM, Achar J, Parpieva N, Khamraev A, Denholm JT, Falzon D, Jaramillo E, Mesic A, du Cros P, McBryde ES.

BMC Med. 2016 Nov 18;14(1):187.

26.

The impact of didactic read-aloud action cards on the performance of cannula cricothyroidotomy in a simulated 'can't intubate can't oxygenate' scenario.

Harvey R, Foulds L, Housden T, Bennett KA, Falzon D, McNarry AF, Graham C.

Anaesthesia. 2017 Mar;72(3):343-349. doi: 10.1111/anae.13643. Epub 2016 Oct 31.

27.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

28.

Lung Isolation for Thoracic Surgery: From Inception to Evidence-Based.

Falzon D, Alston RP, Coley E, Montgomery K.

J Cardiothorac Vasc Anesth. 2017 Apr;31(2):678-693. doi: 10.1053/j.jvca.2016.05.032. Epub 2016 May 20. Review. No abstract available.

PMID:
27595530
29.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P; Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

30.

Digital health for the End TB Strategy: developing priority products and making them work.

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC.

Eur Respir J. 2016 Jul;48(1):29-45. doi: 10.1183/13993003.00424-2016. Epub 2016 May 26.

31.

Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010.

Milanov V, Falzon D, Zamfirova M, Varleva T, Bachiyska E, Koleva A, Dara M.

Int J Mycobacteriol. 2015 Jun;4(2):131-7. doi: 10.1016/j.ijmyco.2015.03.005. Epub 2015 Apr 17.

32.

Monitoring Therapy Compliance of Tuberculosis Patients by using Video-Enabled Electronic Devices.

Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, Oprunenco A, Collins K, Sarin R, Quraishi S, Sharma M, Migliori GB, Varadarajan M, Falzon D.

Emerg Infect Dis. 2016 Mar;22(3):538-40. doi: 10.3201/eid2203.151620.

33.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
34.

Numbers needed to treat to prevent tuberculosis.

Matteelli A, Lönnroth K, Getahun H, Falzon D, Migliori GB, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1838-9. doi: 10.1183/13993003.01179-2015. No abstract available.

35.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

36.

Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus.

Khaliaukin A, Kumar AM, Skrahina A, Hurevich H, Rusovich V, Gadoev J, Falzon D, Khogali M, de Colombani P.

Public Health Action. 2014 Oct 21;4(Suppl 2):S24-8. doi: 10.5588/pha.14.0042.

37.

The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation.

Falzon D, Raviglione M, Bel EH, Gratziou C, Bettcher D, Migliori GB.

Eur Respir J. 2015 Aug;46(2):307-11. doi: 10.1183/09031936.00043315. No abstract available.

38.

WHO's new end TB strategy.

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M; for WHO's Global TB Programme.

Lancet. 2015 May 2;385(9979):1799-1801. doi: 10.1016/S0140-6736(15)60570-0. Epub 2015 Mar 24. No abstract available.

PMID:
25814376
39.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

40.

Marfan syndrome presenting with postpartum aortic dissection following dural puncture headache and epidural blood patch.

Humphrey V, Falzon D, Clark V.

Int J Obstet Anesth. 2015 May;24(2):197-8. doi: 10.1016/j.ijoa.2015.01.009. Epub 2015 Feb 7. No abstract available.

PMID:
25790894
41.

Progress in achieving universal access to care for multidrug- resistant tuberculosis (MDR-TB).

Wares F, Falzon D.

Indian J Tuberc. 2014 Oct;61(4):298-306. Review.

PMID:
25675692
42.

Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone.

Falzon D, Hill G, Pal SN, Suwankesawong W, Jaramillo E.

Bull World Health Organ. 2014 Dec 1;92(12):918-9. doi: 10.2471/BLT.14.142570. Epub 2014 Oct 7. No abstract available.

43.

Community-Based Family Health History Education: The Role of State Health Agencies in Engaging Medically Underserved Populations in Understanding Genomics and Risk of Chronic Disease.

Senier L, Shields M, Lee R, Nicoll L, Falzon D, Wiecek E.

Healthcare (Basel). 2015 Oct 21;3(4):995-1017. doi: 10.3390/healthcare3040995.

44.

Tuberculosis control: hard questions.

Weyer K, Falzon D, Wares F, Jaramillo E, Raviglione M.

Lancet. 2014 Nov 15;384(9956):1744. doi: 10.1016/S0140-6736(14)62065-1. Epub 2014 Nov 14. No abstract available.

PMID:
25455240
45.

Drug resistance and tuberculosis elimination in low-incidence countries.

Falzon D, Zellweger JP, Migliori GB, Jaramillo E.

Eur Respir J. 2014 Dec;44(6):1408-11. doi: 10.1183/09031936.00138014. No abstract available.

46.

Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M.

Eur Respir J. 2015 Jan;45(1):150-60. doi: 10.1183/09031936.00101814. Epub 2014 Sep 26.

47.

Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.

Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, Hoffmann H, Hoffner S, Floyd K.

Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28. Review.

48.

The city, its people, their health and tuberculosis.

Falzon D.

Euro Surveill. 2014 Mar 6;19(9). pii: 20721. No abstract available.

49.

HIV and multidrug-resistant tuberculosis: overlapping epidemics.

Dean AS, Zignol M, Falzon D, Getahun H, Floyd K.

Eur Respir J. 2014 Jul;44(1):251-4. doi: 10.1183/09031936.00205413. Epub 2014 Feb 13. No abstract available.

50.

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF.

BMJ Open. 2014 Jan 2;4(1):e004143. doi: 10.1136/bmjopen-2013-004143. Review.

Supplemental Content

Loading ...
Support Center